




Figure 1




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 2E




Figure 2F




Figure 2G




Figure 3A




Figure 3B




Figure 3C




Figure 4A




Figure 4B




Figure 4C




Figure 4D




Figure 4E




Figure 4F




Figure 4G




Figure 5A




Figure 5B




Figure 6A




Figure 6B





Figure 7




Figure 8

MY010 COMPLEMENTATION GROUPS							
	Group 1	Group 2	Group 3				
Coated antibody	MY010-25-3D3	MY010-4E1	MY010-17B10	MY010-3F1	MY010-6C9	MY010-13A2	
MY010-17B10	5.0	3.1	100.3	102.0	102.0	102.0	
MY010-3F1	11.4	13.9	93.0	100.2	100.2	100.3	
MY010-6C9	2.4	7.7	97.7	101.2	100.3	100.8	
MY010-13A2	10.4	13.7	97.7	98.8	99.2	100.0	
Summary of % inhibition (relative) at the highest concentration of antibody (80 nM)							
competing	>80%						
not competing	<20%						

Figure 9




Figure 10




Figure 11A




Figure 11B




Figure 11C




Figure 11D




Figure 12A




Figure 12B




Figure 13A




Figure 13B




Figure 13C




Figure 14A




Figure 14B





Figure 15

C



D




Figure 15 cont.

■ surface-exposed residues of Bet v 1

10 20 30 40 50
MG■FNY■TEA■TSV■IPAARLF■KAFILDGDNL■FPK■VAPQ■AIS■SVENIE■G■NGG
60 70 80 90 100
PGT■KK■ISFP■RGFPF■KYVKD■RVDEVDHTNF■KYNYSVIE■GG■PIGDTLE■KIS
110 120 130 140 150
NE■IKI■VATPD■GGSTL■KISNK■Y■TKG■DHEVK■AEQV■KASK■M■GETLLRAVES■
160
YLL■AHSDAYN■

D/E -> A/K

K/R -> A/E

A -> S/K

Rest-> A

Total number of mutants = 92

Figure 16A




Figure 16B